Merck (MRK) announced that the European Commission has approved Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of resectable locally advanced head and neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumors express PD-L1 with a Combined Positive Score (CPS) greater than or equal to1. This approval marks the first and only anti-PD-1 treatment option for certain patients with resectable LA-HNSCC in the European Union and the third approval for Keytruda in HNSCC in the EU.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Five Blue-Chip Dividend Stocks Built to Outlast the Market Cycle
- Merck reports ‘positive’ results from Phase 3 LITESPARK-022 trial
- Merck, Eisai: Phase 3 LITESPARK-011 trial met primary endpoints
- Merck & Company (MRK) Q3 Earnings Cheat Sheet
- Options Volatility and Implied Earnings Moves This Week, October 28 – October 31, 2025